Evidence map›Paper›PMID 28655286›Full record

ArticleJournal of psychopharmacology (Oxford, England)2017

A group II metabotropic glutamate receptor 3 (mGlu3, GRM3) isoform implicated in schizophrenia interacts with canonical mGlu3 and reduces ligand binding.

Aintzane García-Bea, Isabel Bermudez, Paul J Harrison, Tracy A Lane

Open access · hybridAbstract read
In one paragraph

Article in Journal of psychopharmacology (Oxford, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Activating mGluBiological psychiatry · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Aintzane García-Bea1 Department of Psychiatry, University of Oxford, Warneford Hospital, UK.
Isabel Bermudez2 Oxford Brookes University, Oxford, UK.
Paul J Harrison1 Department of Psychiatry, University of Oxford, Warneford Hospital, UK.
Tracy A Lane1 Department of Psychiatry, University of Oxford, Warneford Hospital, UK.
Warneford Hospital · GBOxford Brookes University · GB

Funding

Medical Research Council G0801747Wellcome Trust
6 · The paper itself

Abstract

As well as being expressed as a full-length transcript, the group II metabotropic glutamate receptor 3 (GRM3, mGlu3) gene is expressed as an mRNA isoform which lacks exon 4 (GRM3Δ4) and which is predicted to encode a protein with a novel C terminus (called mGlu3Δ4). This variant may contribute to the mechanism by which GRM3 acts as a schizophrenia risk gene. However, little is known about the properties or function of mGlu3Δ4. Here, using transiently transfected HEK293T/17 cells, we confirm that GRM3Δ4 cDNA is translated, with mGlu3Δ4 existing as a homodimer as well as a monomer, and localizing primarily to cell membranes including the plasma membrane. Co-immunoprecipitation shows that mGlu3Δ4 interacts with canonical mGlu3. mGlu3Δ4 does not bind the mGlu2/3 antagonist [

Indexed as

Amino AcidsCell MembraneHEK293 CellsHumansLigandsProtein IsoformsRadioligand AssayReceptors, Metabotropic GlutamateSchizophreniaTransfectionTritiumXanthenesAmino AcidsLigandsLY 341495metabotropic glutamate receptor 3Protein IsoformsReceptors, Metabotropic GlutamateTritiumXanthenesalternative splicingG protein-coupled receptorisoformMetabotropic glutamate receptorschizophrenia

Identifiers

PMID28655286
PMCPMC5714154
OpenAlexW2728674636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.